Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Diabetes / Metabolic Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting NCT05006196

Contrast-Free Magnetic Resonance Imaging for Breast Disease

Contrast-Free Magnetic Resonance Imaging for Breast Disease — Active Not Recruiting • Oncology • NCT05006196.

📅 20 May 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
NCT ID
NCT05006196
Start
2021-07-06
Completion
2026-12-31
ClinicaliQ Trial Snapshot
  • Contrast-Free Magnetic Resonance Imaging for Breast Disease — Active Not Recruiting • Oncology • NCT05006196.
  • MRI without contrast dye can accurately diagnose breast cancer in women at risk or with suspected disease.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Prospective, observational cohort study looking at patients either at risk of breast cancer or have clinically suspected breast to assess the diagnostic performance of quantitative, non-contrast MRI. Conditions: Breast Cancer, Breast Diseases Interventions: Outpatient MRI Lead Sponsor: Perspectum Planned Enrollment: 1030 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more lines of anti-HER2 treatment
Oncology · 20 Oct 2026
Trastuzumab deruxtecan is recommended as an option for HER2-positive unresectable or metastatic breast cancer only after 1 or more prior lines of…
View guideline →
Clinical Brief
Haematology centre for cancer patients at risk over ‘disgraceful’ funds move
Oncology · BBC Health · 22 Oct 2026
The Department of Health is withdrawing £1.5m funding from a haematology centre serving cancer patients in Belfast, creating significant financial jeopardy for…
View brief →
Guideline
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Oncology · 07 Oct 2026
Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low metastatic or unresectable breast cancer, making it suitable for patients…
View guideline →
Clinical Brief
Free counselling for blood cancer patients
Oncology · BBC Health · 24 Sep 2026
Linc provides free counselling services accessible to blood cancer patients at all diagnostic stages and their families, addressing psychological support gaps in…
View brief →
Clinical Brief
New hope for breast cancer patients as life-extending drug now on NHS in England
Oncology · BBC Health · 16 Sep 2026
Enhertu is now available on the NHS in England, extending median overall survival by approximately seven months in eligible breast cancer patients…
View brief →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →